JC
ABUS icon

JBF Capital’s Arbutus Biopharma ABUS Stock Holding History

JBF Capital’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$361K Buy
+80,281
New +$351K 0.05% 76
2014
Q2 		– Sell
-60,410
Closed -$1.3M – 91
2014
Q1 		$1.3M Buy
+60,410
New +$1.09M 0.2% 30

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

JBF Capital's ABUS Position: Q1 2026 in Review

JBF Capital opened a new position in Arbutus Biopharma (ABUS) in Q1 2026: 80,281 shares worth $361K. The stake represents 0.05% of the portfolio and ranks #76 among its holdings. This is a return to the name: JBF Capital previously reported a position in ABUS as recently as Q1 2014.

JBF Capital first reported a position in ABUS in Q1 2014 and has held it in 2 quarters since. The position peaked at $1.3M in Q1 2014. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • JBF Capital held 80,281 shares of Arbutus Biopharma worth $361K as of Q1 2026.
  • Arbutus Biopharma was a new JBF Capital position in Q1 2026.
  • Arbutus Biopharma made up 0.05% of JBF Capital's portfolio in Q1 2026, its #76 holding.
  • JBF Capital first reported a position in Arbutus Biopharma in Q1 2014 and has held it in 2 quarters since.
  • JBF Capital's Arbutus Biopharma position peaked at $1.3M in Q1 2014.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on JBF Capital's 13F filing for Q1 2026, filed 8 May 2026.